Related Articles
Response to erlotinib in a patient with lung adenocarcinoma harbouring the EML4-ALK translocation: A case report
ALK‑positive locally advanced lung cancer in a patient who achieved long‑term complete response with crizotinib: A case report
Heterogeneity of epidermal growth factor receptor mutations in lung adenocarcinoma harboring anaplastic lymphoma kinase rearrangements: A case report
Marked tumor response to crizotinib after 4 years of maintenance pemetrexed in a patient with anaplastic lymphoma kinase‑positive non‑small‑cell lung cancer
Comparison of the characteristics of uncommon epidermal growth factor receptor (EGFR) mutations and EGFR‑tyrosine kinase inhibitor treatment in patients with non‑small cell lung cancer from different ethnic groups